antiinflammatory drug

(redirected from Nepafenac)
Also found in: Wikipedia.

antiinflammatory drug 

A drug which inhibits or suppresses most inflammatory responses of an allergic, bacterial, traumatic or anaphylactic origin, as well as being immunosuppressant. They include the corticosteroids (e.g. betamethasone, dexamethasone, fluorometholone, hydrocortisone acetate, loteprednol etabonate, prednisolone, rimexolone, triamcinolone). They are sometimes combined with an antibiotic drug (e.g. betamethasone combined with neomycin or sulfacetamide, dexamethasone combined with neomycin or polymyxin B). Corticosteroids have side effects, such as enhancing the activity of herpes simplex virus, fungal overgrowth, raising intraocular pressure or cataract formation.There are other antiinflammatory drugs that are non-steroidal (NSAID) and have little toxicity. They act mainly by blocking prostaglandin synthesis. These include diclofenac sodium, flurbiprofen sodium, indomethacin, ketorolac, nepafenac and oxyphenbutazone. See immunosuppressants; steroid.
Millodot: Dictionary of Optometry and Visual Science, 7th edition. © 2009 Butterworth-Heinemann
References in periodicals archive ?
M2 PHARMA-May 10, 2019-Mati Therapeutics Phase II Nepafenac Evolute Clinical Trial Results Show Significant Post-Operative Pain Reduction in Cataract Surgery Patients
Treatment with nepafenac drops 4 times daily was started in the left eye.
Postoperatively, 0.5% moxifloxacin six times a day, prednisolone acetate 1% six times a day and nepafenac ophthalmic suspension 0.1% three times a day were used.
One of them is nepafenac (Nevanac[R], Alcon), which is a topical nonsteroidal drug that has shown great efficacy to treat DME [45].
Bandage contact lens was placed at the end of procedure and patients were advised with topical moxifloxacin, nepafenac and cyclopentolate eye drops three times a day for 1 week.
The five drugs in this class are bromfenac (Xibrom), diclofenac (Voltaren), flurbiprofen (Ocufen), ketorolac, and nepafenac (Nevanac).
The company has completed multiple Phase II clinical trials using the Evolute platform and recently announced interim results from a Phase II study of nepafenac versus placebo in patients undergoing cataract surgery.
Treatment was started with topical nepafenac 0.1% (Nevanac Alcon, Forth Worth, Texas, United States of America) 3 times a day.
utilized nepafenac one day prior to FLACS and demonstrated significant reduction of prostaglandin concentration in the aqueous humor when compared even with manual cataract surgery [20].